-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 17, 2021, Corning Jerry sponsored the "Multicenter Phase III clinical study of the efficacy and safety of KN046 combined with platinum-containing chemotherapy versus placebo combined with platinum-containing chemotherapy in patients with advanced squamous non-small cell lung cancer" (Research Number: ENREACH-LUNG-01) Interim Researchers' Meeting was held in Hangzhou
.
More than 70 researchers including Professor Zhou Caicun, Director of Oncology Department of Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Xu Nong, Director of Oncology Department of Zhejiang University First Affiliated Hospital, etc.
ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer.
Professor Zhou Caicun of the Pulmonary Hospital serves as the main researcher, and is conducting research in more than 60 research centers across the country.
It plans to recruit about 500 patients to evaluate the safety and effectiveness of combined chemotherapy at the dose of KN046-5mg
.
At the meeting, Professor Zhou Caicun, Director of the Oncology Department of Shanghai Pulmonary Hospital Affiliated to Tongji University, gave an opening speech.
From the perspective of global academic research in the field of lung cancer treatment, he highly praised the ENREACH-LUNG-01 trial of KN046 and placed high hopes.
Professor Zhou Caicun said: "Immunotherapy is an important research progress in the field of lung cancer treatment.
Many international studies have shown the light for patients, but the overall prognosis and long-term efficacy of patients still need to be improved
.
Corning Jereh is a leader among Chinese tumor immunotherapy pharmaceutical companies.
Dr.
Xu Ting, Chairman and President of Corning Jerry, delivered a welcome speech, giving an outline of Corning Jerry's research and development in the field of anti-tumor biological drugs
.
Dr.
Dr.
Johannes Nippgen, Chief Medical Officer of Corning Jerry, focused on the development strategy and clinical development plan of new drugs in the clinical phase
The meeting was hosted by Professor Zhou Caicun, Director of Oncology Department of Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Xu Nong, Director of Oncology Department of Zhejiang University First Affiliated Hospital, Professor Xiong Anwen of Shanghai Pulmonary Hospital and Professor Li Xingya of First Affiliated Hospital of Zhengzhou University respectively shared ENREACH -LUNG-01 clinical research experience and non-small cell lung cancer research progress.
